ليتروزول تيڤع

Ülke: İsrail

Dil: Arapça

Kaynak: Ministry of Health

Aktif bileşen:

LETROZOLE 2.5 MG

Mevcut itibaren:

TEVA PHARMACEUTICAL INDUST.LTD

ATC kodu:

L02BG04

Farmasötik formu:

TABLETS

Uygulama yolu:

PER OS

Tarafından üretildi:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapötik grubu:

LETROZOLE

Terapötik endikasyonlar:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Yetkilendirme tarihi:

2010-01-01